IOL Chemicals And Pharmaceuticals Q2 Results FY27: PAT Jumps 117.12% to Rs 65.07 Cr, Revenue Rs 795.03 Cr
- October 31, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
IOL Chemicals And Pharmaceuticals Q2 Results FY27 were declared on 30 October 2026 and show consolidated results with revenue of Rs 795.03 Cr, up 40.09% from Rs 567.53 Cr a year earlier. Net profit stood at Rs 65.07 Cr against Rs 29.97 Cr, a rise of 117.12%. These quarterly results show strong YoY growth in both lines.
IOL Chemicals And Pharmaceuticals Ltd (IOLCP) Q2 Results FY27 announced on 30 October 2026, covering the company’s financial performance for the July to September quarter. The consolidated results show revenue of Rs 795.03 Cr and net profit of Rs 65.07 Cr, and IOL Chemicals And Pharmaceuticals Q2 Results FY27 reveal a clear step up from the same quarter last year. The results date marks the point where the new numbers became public.
This results analysis of IOL Chemicals And Pharmaceuticals Q2 Results covers the financial highlights, the business drivers, the outlook and the risks, so readers can see how the quarter was built. The Financial Highlights table below sets the headline numbers side by side.
Click Here – Get Free Investment Predictions
IOL Chemicals And Pharmaceuticals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 795.03 Cr | Rs 567.53 Cr | +40.09% YoY |
| Operating Profit | Rs 109.42 Cr | Rs 57.08 Cr | +91.7% YoY |
| Net Profit (PAT) | Rs 65.07 Cr | Rs 29.97 Cr | +117.12% YoY |
Source: company filing for IOL Chemicals And Pharmaceuticals Q2 Results FY27, 30 October 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from IOL Chemicals And Pharmaceuticals Q2 Results: What Stands Out
- Revenue rose 40.09% to Rs 795.03 Cr from Rs 567.53 Cr in the same quarter last year, a sharp expansion in the top line.
- Net profit climbed 117.12% to Rs 65.07 Cr, more than double the Rs 29.97 Cr reported a year earlier, as IOL Chemicals And Pharmaceuticals Q2 Results FY27 confirm.
- Operating Profit reached Rs 109.42 Cr against Rs 57.08 Cr last year, a YoY growth of 91.7% in the middle profit line.
- Net profit margin improved to 8.2% from 5.3% in the comparison quarter, so profit grew faster than revenue.
- Revenue has risen in each of the last 4 quarters, and the performance analysis below explains how these figures fit together.
IOL Chemicals And Pharmaceuticals Q2 Results FY27: Performance Analysis
IOL Chemicals And Pharmaceuticals show that the company grew both revenue and profit at a fast pace. Revenue reached Rs 795.03 Cr against Rs 567.53 Cr, while net profit moved to Rs 65.07 Cr from Rs 29.97 Cr. Profit therefore expanded much faster than sales this quarter.
The Operating Profit line tells the same story. It stood at Rs 109.42 Cr compared with Rs 57.08 Cr a year earlier, which is a rise of 91.7%. Revenue growth of 40.09% was outpaced by Operating Profit growth, and net profit growth of 117.12% went further still, which is the pattern investors will watch in the next disclosures.
In IOL Chemicals And Pharmaceuticals Q2 Results the consolidated results capture the full group, so the figures reflect all reporting businesses together. These quarterly results give a clean YoY growth comparison for the July to September 2026 period, and the same results analysis points straight to the business factors behind the numbers.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Strong Revenue Expansion – The results analysis points to revenue growth of 40.1% year on year to Rs 795.03 Cr as the first factor in the quarterly results. A larger top line gave the company more room to absorb costs and lift profit.
Better Net Profit Margin – Net profit margin improved to 8.2% from 5.3% in the comparison quarter, so a larger share of each rupee of revenue reached the bottom line in IOL Chemicals And Pharmaceuticals Q2 Results FY27.
Four Quarters of Rising Revenue – Revenue has risen in each of the last 4 quarters, which shows that the Rs 795.03 Cr reported now follows a run of steady sequential increases rather than a single jump.
FY27 Outlook After IOL Chemicals And Pharmaceuticals Q2 Results
The full-year FY27 picture will depend on the quarters still to be reported, and this single quarter should be read as one data point. IOL Chemicals And Pharmaceuticals Q2 Results FY27 give a strong starting reference, with net profit of Rs 65.07 Cr and revenue of Rs 795.03 Cr on a Consolidated basis.
A results analysis for the rest of FY27 will need to track whether revenue keeps rising and whether net profit holds near the current level. Investors can follow upcoming disclosures from the company on NSE and BSE, and the risks that matter most are listed next.
Key Risks to Watch After IOL Chemicals And Pharmaceuticals Q2 Results FY27
Low Return on Equity
Return on equity was low at 7.90% in FY26, which means the profit earned on shareholder capital remains modest even as the latest quarter improved. IOL Chemicals And Pharmaceuticals Q2 Results FY27 should be read alongside this longer-term measure.
Lower Profit Per Share Over Time
Annual profit per share has slipped from Rs 5.71 in FY22 to Rs 4.69 in FY26, so the strong YoY growth in the latest quarter has yet to reverse the multi-year trend seen in the annual figures.
Volatile Quarterly Net Profit
Quarterly net profit has been volatile, ranging from Rs 20.58 Cr to Rs 65.07 Cr over the last 5 quarters, so the current level may not repeat each quarter and the swings deserve attention.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
IOL Chemicals And Pharmaceuticals Q2 Results FY27 show consolidated revenue of Rs 795.03 Cr and net profit of Rs 65.07 Cr, both sharply higher than a year ago. These quarterly results make IOL Chemicals And Pharmaceuticals Q2 Results a strong reference point for the FY27 story. Investors should consult a SEBI-registered advisor before acting on any of this information.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on IOL Chemicals And Pharmaceuticals Q2 Results FY27
What are IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. IOL Chemicals And Pharmaceuticals Q2 Results FY27 are the Consolidated results of IOL Chemicals And Pharmaceuticals Ltd for July to September 2026, with revenue of Rs 795.03 Cr. Alongside this, the Quick Answer summarises the headline numbers.
What is the results date for IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. The results date for IOL Chemicals And Pharmaceuticals Q2 Results FY27 was 30 October 2026, when the company announced its quarterly results. This is the date that the opening section of the article refers to.
What revenue was reported in IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. IOL Chemicals And Pharmaceuticals Q2 Results FY27 reported revenue of Rs 795.03 Cr, compared with Rs 567.53 Cr a year earlier, which means revenue grew 40.09% YoY, as the Financial Highlights table shows.
What net profit was reported in IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. IOL Chemicals And Pharmaceuticals Q2 Results FY27 reported net profit of Rs 65.07 Cr against Rs 29.97 Cr, a rise of 117.12%, so profit more than doubled, as the Key Takeaways section explains.
How much YoY growth did revenue show in IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. Revenue showed YoY growth of 40.09% in IOL Chemicals And Pharmaceuticals Q2 Results FY27, moving from Rs 567.53 Cr to Rs 795.03 Cr, while the Performance Analysis section compares this with profit growth.
Did net profit rise or fall in IOL Chemicals And Pharmaceuticals Q2 Results?
Ans. Net profit rose in IOL Chemicals And Pharmaceuticals Q2 Results, climbing 117.12% to Rs 65.07 Cr from Rs 29.97 Cr, which means profit grew faster than revenue, as the Performance Analysis section describes.
What was the Operating Profit in IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. Operating Profit in IOL Chemicals And Pharmaceuticals Q2 Results FY27 was Rs 109.42 Cr against Rs 57.08 Cr a year earlier, a rise of 91.7%, which is covered in the Key Takeaways section.
Are IOL Chemicals And Pharmaceuticals Q2 Results consolidated results or standalone results?
Ans. IOL Chemicals And Pharmaceuticals Q2 Results are consolidated results, so the figures cover the full group rather than a single entity. Alongside this, the Quick Answer and Performance Analysis sections state the consolidated basis.
What business factors shaped IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. IOL Chemicals And Pharmaceuticals Q2 Results FY27 were shaped by 40.1% revenue growth, an improved net profit margin of 8.2% from 5.3%, and four straight quarters of rising revenue, as the Key Business Factors section details.
What are the key risks after IOL Chemicals And Pharmaceuticals Q2 Results FY27?
Ans. Key risks after IOL Chemicals And Pharmaceuticals Q2 Results FY27 include a low return on equity of 7.90% in FY26, lower annual profit per share since FY22, and volatile quarterly net profit, as the Key Risks section explains.
What is the outlook after IOL Chemicals And Pharmaceuticals Q2 Results?
Ans. The outlook after IOL Chemicals And Pharmaceuticals Q2 Results depends on upcoming quarters, since full-year FY27 results are not yet complete, which means readers should track later disclosures, as the Outlook section notes.
Where can I find the complete IOL Chemicals And Pharmaceuticals Q2 Results FY27 data?
Ans. The complete IOL Chemicals And Pharmaceuticals Q2 Results FY27 data is in the Financial Highlights table of this article, which lists revenue, Operating Profit and net profit with YoY change, alongside the opening analysis.
